bleeding trauma patient has evolved in the last decade. A significant paradigm shift has occurred and the focus has gone from fluid resuscitation (primarily with crystalloids) to bleeding control first accompanied by early transfusion of blood and blood products to overcome the effects of injury and blood lossinduced coagulopathy. Two new concepts emerged from this paradigm shift: 1) Permissive Hypotension and 2) Damage Control Resuscitation. Data from the US military obtained during the last decade of military conflict in the Middle East demonstrated that using less crystalloids, focusing on bleeding control and using whole blood (if available) or a higher ratio of Fresh Frozen Plasma (FFP) to PRBC and Platelets (1:1:1) improves outcomes. Several studies have concluded that the principles of resuscitation proposed in the military studies are also applicable to the civilian environment. Others have also evaluated the use of fibrinogen and cryoprecipitate as adjuncts to PRBC, FFP, and Platelets, concluding that blood loss, transfusion requirements, and mortality are decreased when these products are used. In addition, other adjuncts such as Tranexemic Acid, Prothrombin Complex, and Activated Factor VIIa have been shown to affects outcomes when used appropriately, at the right time, and in the right patient.
Massive Transfusion Protocols exist to meet the requirements of Damage Control Resuscitation. The strategy includes starting blood early as the first line of fluid replacement, delivering O negative blood first, followed by type specific as soon as possible, and maintaining a steady supply at a PRBC;FFP:PLT ratio as close to 1:1:1, until it is no longer necessary. The goals are to treat traumatic coagulopathy at presentation, prevent dilutional coagulopathy, and prevent complications associated with massive hemorrhage/transfusion. Using classic transfusion triggers such as 6 U to 10 U of PRBC) to initiate FFP and Platelet transfusion will only delay early correction of coagulopathy.
Any institution treating injured patients should have a an "Institutional Massive Transfusion Protocol" in place. Several studies comparing periods of time pre and post the implementation of a massive transfusion protocol have consistently demonstrated an increased ratio of PRBC:FFP, earlier initiation of transfusion, decreased crystalloid use, and decreased mortality at 24 h and 30 d. Other have also shown decreased overall usage of blood products, decreased cost and decreased morbidity such as pneumonia, acute kidney injury, abdominal compartment syndrome, ARDS, sepsis, septic shock, and multiple organ failure. Whether massive transfusion protocols should be "laboratory-directed" or protocol driven is still a matter of discussion. The turnaround times for classic coagulation tests varies from 30-60 minutes and their accuracy is questionable in hypothermic patients. It seems that if one decides to use a laboratory-directed massive transfusion protocol it must be based on Thromboelastogram (TEG/ROTEM) findings, which have shown to predict and trigger the initiation of a massive transfusion protocol and are also applicable for ongoing goal-directed blood component therapy.
In summary, massive transfusion protocols improve immediate availability of blood products, likely decrease mortality when used effectively and timely, and may decrease costs and blood product utilization. A massive transfusion protocol should be tailored to the types of patients treated at the institution and should be embraced not only by the trauma surgeons, but also by transfusion medicine, emergency medicine, and other surgical specialties. Consistency in timely blood product delivery saves lives.
